Abstract
Research and development (R&D) and pricing, access, and reimbursement (PAR) barriers often prevent innovative therapies from reaching patients in a timely manner. Rapid R&D and PAR strategies have allowed COVID-19 vaccines to become available globally. We compare COVID-19 vaccines with other innovative therapies with expedited approvals to learn from and potentially model future frameworks when bringing new therapies to market.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
